ArticleFrontiers in pharmacology2022

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.

Frontiers Production OfficePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.